Treatment and Management of Myasthenia Gravis

Dr. Pushpa Narayanaswami and Dr. Michael Hehir discuss new guidelines and emerging therapies for the treatment of Myasthenia Gravis.

Dr. Narayanasawmi discloses consulting fees from Janssen/Momenta, Alexion, Argenx, and UCB. Dr. Narayanaswami also discloses lecture fees or honoraria from UCB, Argenx, and Alexion. Dr. Narayanaswami discloses grant support from Alexion. Dr. Hehir discloses consulting fees or paid advisory boards from Argenx, Alexion, and UCB Pharma. Dr. Hehir also discloses grant support from the MGFA Innovations grant, and UVM Medical Center Innovations Grant.